- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00066547
Monoclonal Antibody Therapy in Treating Women With Locally Advanced or Metastatic Breast Cancer Previously Treated With Combination Chemotherapy
An Open Label Phase I/II Study of Humanized Human Milk Fat Globule-1 (THEREX) in Patients With Locally Advanced or Metastatic Breast Cancer Following Prior Anthracycline and Taxane Therapy
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
PURPOSE: Phase I/II trial to study the effect of monoclonal antibody therapy on the body and its effectiveness in treating women who have locally advanced or metastatic breast cancer that was previously treated with combination chemotherapy.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
OBJECTIVES:
- Determine the safety and tolerability of monoclonal antibody HuHMFG1 in women with locally advanced or metastatic breast cancer previously treated with anthracycline and taxane-based therapy.
- Determine the maximum tolerated dose and appropriate schedule of this drug in these patients.
- Determine the pharmacokinetic profile of this drug in these patients.
- Determine the tumor response rate, progression-free survival, and median survival of patients treated with this drug.
- Analyze immunological markers for evaluation of disease status (e.g., in vitro analysis of antibody-dependent cellular cytotoxicity, natural killer cell activity, complement depletion, and tumor markers CA 15.3 and CEA) in patients treated with this drug.
OUTLINE: This is a dose-escalation, open-label, nonrandomized, multicenter study.
- Phase I: Patients receive monoclonal antibody HuHMFG1 IV over 1-3 hours once every 3 weeks for doses 1 and 2. All subsequent dose intervals are based on individual half-life value of the drug. Patients receive at least 6 doses in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of monoclonal antibody HuHMFG1 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
- Phase II:Patients receive monoclonal antibody HuHMFG1 as above at the MTD. Patients are followed at 28 days.
PROJECTED ACCRUAL: Approximately 3-40 patients (3-15 patients for phase I and 19-25 patients for phase II) will be accrued for this study within approximately 12 months.
Tipo de estudo
Estágio
- Fase 2
- Fase 1
Contactos e Locais
Locais de estudo
-
-
California
-
Los Angeles, California, Estados Unidos, 90095-1781
- Jonsson Comprehensive Cancer Center, UCLA
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed breast cancer
- Locally advanced or metastatic disease
- No inflammatory breast cancer
- Polymorphic epithelial mucin (PEM) antigen overexpression by immunohistochemistry
Previously treated with an anthracycline and a taxane in any combination for breast cancer
- No more than 2 prior chemotherapy regimens, including adjuvant /neoadjuvant therapy
- No more than 1 prior regimen for distant metastatic disease
- Any number of prior hormonal or biologic therapy regimens allowed
Measurable disease
- At least one unidimensionally measurable lesion not previously irradiated
The following are not considered measurable lesions:
- Bone
- Leptomeningeal disease
- Ascites
- Pleural/pericardial effusion
- Lymphangitis cutis/pulmonis
- Abdominal masses not confirmed and followed by imaging techniques
- Cystic lesions
- No metastases accessible to complete surgical resection
- No CNS metastasis by CT scan
Hormone receptor status:
- Not specified
PATIENT CHARACTERISTICS:
Age
- 18 and over
Sex
- Female
Menopausal status
- Not specified
Performance status
- WHO 0-2
Life expectancy
- At least 4 months
Hematopoietic
- Hemoglobin at least 10 g/dL
- Neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
Hepatic
- Bilirubin no greater than 1.5 mg/dL
- ALT and AST no greater than 2.5 times upper limit of normal (ULN) (less than 5 times ULN if liver metastases are present)
Renal
- Creatinine no greater than 1.5 times ULN OR
- Creatinine clearance greater than 60 mL/min
- No hyperuricemia (uric acid at least 1.25 times ULN)
- No hypercalcemia (calcium at least 11.5 mg/dL [corrected for serum albumin])
Cardiovascular
- LVEF at least 45% by MUGA or echocardiogram within the past 4 weeks
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 3-6 months after study participation
- No other prior malignancy within the past 5 years except adequately treated nonmelanoma skin cancer or cervical intraepithelial neoplasia
- No other concurrent uncontrolled comorbid illness that represents unacceptable risk in the opinion of the investigator
- No legal incapacity
PRIOR CONCURRENT THERAPY:
Biologic therapy
- See Disease Characteristics
- More than 2 weeks since prior growth factors to aid hematologic recovery
- No other concurrent immunotherapy
Chemotherapy
- See Disease Characteristics
- More than 4 weeks since prior cytotoxic chemotherapy
- No concurrent chemotherapy for metastatic breast cancer
Endocrine therapy
- See Disease Characteristics
- No concurrent endocrine therapy for metastatic breast cancer
- No concurrent chronic corticosteroid therapy
- No concurrent high-dose corticosteroids
Radiotherapy
- More than 4 weeks since prior radiotherapy except for palliation
- No concurrent antitumor radiotherapy except for palliation
Surgery
- More than 4 weeks since prior major surgery
Other
- More than 2 weeks since prior blood transfusions to aid hematologic recovery
- No participation in any other investigational drug study
- No other concurrent investigational drugs
- No other concurrent antitumor therapy
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Mascaramento: Nenhum (rótulo aberto)
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Mark D. Pegram, MD, Jonsson Comprehensive Cancer Center
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CDR0000316264
- UCLA-0212097
- ANTISOMA-TOPCAT
- ANTISOMA-ASM-THEREX-01
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Câncer de mama
-
Turku University HospitalLounais-Suomen SyöpäyhdistysAinda não está recrutandoSobrevivente de cancerFinlândia
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RetiradoSobrevivente de cancerEstados Unidos
-
University of Alabama at BirminghamNational Cancer Institute (NCI); Auburn UniversityConcluído
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)ConcluídoSobrevivente de cancerEstados Unidos
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)ConcluídoSobrevivente de cancerEstados Unidos, Guam
-
Wake Forest University Health SciencesNational Cancer Institute (NCI); National Institute of Mental Health (NIMH)ConcluídoSobrevivente de cancerEstados Unidos
-
Masonic Cancer Center, University of MinnesotaConcluídoSobrevivente de cancerEstados Unidos
-
Abramson Cancer Center of the University of PennsylvaniaConcluídoPlano de cuidados de sobrevivência LIVESTRONG: coleta contínua de dados e pesquisa de acompanhamentoPaciente com cancerEstados Unidos
-
University of New MexicoNew Mexico State University; University of New Mexico Cancer CenterConcluído
-
Ohio State University Comprehensive Cancer CenterConcluídoSobrevivente de cancerEstados Unidos
Ensaios clínicos em anticorpo monoclonal HuHMFG1
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)ConcluídoCâncer de mamaEstados Unidos
-
Lumos DiagnosticsRapid Pathogen ScreeningConcluídoSARS-Cov-2, Covid19Estados Unidos
-
Mersana TherapeuticsGOG Foundation; European Network of Gynaecological Oncological Trial Groups...RescindidoCâncer de Trompa de Falópio | Câncer Peritoneal Primário | Câncer de ovário seroso de alto grauEstados Unidos, Austrália, Canadá
-
Intergroupe Francophone du MyelomeRecrutamento
-
Antisoma ResearchRescindidoCarcinoma de mamaFederação Russa
-
Temple UniversityDialysis Clinic, Inc.Concluído
-
The Second Affiliated Hospital of Chongqing Medical...RecrutamentoSARS-CoV-2 | PrevençãoChina
-
Macfarlane Burnet Institute for Medical Research...Recrutamento
-
Humanigen, Inc.ConcluídoLeucemia Mielomonocítica Crônica (LMMC)Estados Unidos
-
University of Illinois at ChicagoHiberCell, Inc.RescindidoCâncer de pâncreasEstados Unidos